Lorrany Larisse Costa Rodrigues

Lorrany Larisse Costa Rodrigues

Auto-generated profile, based on publicly available information

Lorrany Larisse Costa Rodrigues

Department of Medical Sciences, Universidad Central del Paraguay, Ciudad del Este, Paraguay

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2026 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
LRLorrany Larisse Costa Rodrigues
Lorrany Larisse Costa Rodrigues
LSLara de Holanda Jucá Silveira
Lara de Holanda Jucá Silveira
LALuiz Felipe C. de Almeida
Luiz Felipe C. de Almeida
BFBianca Gonzaga de Freitas
Bianca Gonzaga de Freitas
VFValbert Oliveira Costa Filho
Valbert Oliveira Costa Filho
FBFelipe Batalini
Felipe Batalini

11 February 2026 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
LRLorrany Larisse Costa Rodrigues
Lorrany Larisse Costa Rodrigues
RSRebeca Ferreira de Souza
Rebeca Ferreira de Souza
BFBianca Gonzaga Freitas
Bianca Gonzaga Freitas
LGLeticia Gomes
Leticia Gomes
VFValbert Oliveira Costa Filho
Valbert Oliveira Costa Filho
OAOtávio Al-Alam
Otávio Al-Alam

31 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
AYAngela Theresa Zuffo Yabrude
Angela Theresa Zuffo Yabrude
LRLeila Caroline Souza Reis
Leila Caroline Souza Reis
AZAna Elisa Saragossa Zafalon
Ana Elisa Saragossa Zafalon
LRLorrany Larisse Costa Rodrigues
Lorrany Larisse Costa Rodrigues
CAClara Fish Araujo de Albuquerque
Clara Fish Araujo de Albuquerque
EMEliza Del Fiol Manna
Eliza Del Fiol Manna
Background: Pembrolizumab plus chemotherapy is the standard perioperative treatment for high-risk stage II–III triple-negative breast cancer (TNBC), based on the overall survival benefit in KEYNOTE-522. In Brazil, pembrolizumab is approved but not funded by the public health system (SUS), which covers ~76% of the population. We estimated the population impact of delayed access.Materials and Methods: A nationwide counterfactual model estimated the consequences of a 10-year delay in pembrolizumab availability within SUS. The annual eligible cohort was derived from breast-cancer incidence, private-coverage data, TNBC prevalence, and the stage II–III proportion. Treatment effect used the 5-year KEYNOTE-522 update (OS 86.6% vs 81.7%; HR 0.66). Preventable deaths were computed from the absolute 5-year mortality reduction and life-years lost from restricted mean survival time, under 95%, 75%, and 50% uptake, with deterministic and probabilistic sensitivity analyses.Results: Of 73,610 annual breast-cancer cases, approximately 5,384 women were eligible within SUS. At 95% uptake, a 10-year delay was associated with 251 preventable deaths per annual cohort 2,506 preventable deaths and 5,156 life-years lost overall, corresponding totals were 1,979 deaths (75%) and 1,319 deaths (50%). Results were most sensitive to treatment effect and TNBC prevalence, and probabilistic analyses consistently supported substantial benefit.Conclusion: Delayed incorporation of perioperative pembrolizumab into SUS is expected to cause substantial avoidable deaths and life-years lost among women with high-risk early TNBC. These estimates quantify the clinical cost of delayed access and may inform health-technology-assessment and reimbursement decisions.